Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 6/20 | 0.49 |
| ▸ | JUN | P05412 | 5/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 5/20 | 0.49 |
| ▸ | TTK | P33981 | 1/20 | 0.47 |
| ▸ | CDK4 | P11802 | 5/20 | 0.47 |
| ▸ | CCND1 | P24385 | 5/20 | 0.47 |
| ▸ | CDK1 | P06493 | 3/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.47 |
| ▸ | CDK2 | P24941 | 3/20 | 0.47 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.45 |
| ▸ | ERBB3 | P21860 | 3/20 | 0.45 |
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
| ▸ | CCND2 | P30279 | 2/20 | 0.45 |
| ▸ | CCND3 | P30281 | 2/20 | 0.45 |
| ▸ | STAT6 | P42226 | 2/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16514802 | 0.96 | JUN (0.47) | MAPK10JUNMAPK8TTKCDK4 | |
| SCHEMBL16515205 | 0.91 | MAPK10 (0.42) | MAPK10JUNMAPK8TTKCDK4 | |
| SCHEMBL29846996 | 0.91 | CDK4 (0.48) | MAPK10JUNMAPK8CDK4CCND1 | |
| SCHEMBL16514858 | 0.91 | CDK4 (0.48) | MAPK10JUNMAPK8CDK4CCND1 | |
| SCHEMBL16514357 | 0.90 | MAPK10 (0.57) | MAPK10JUNMAPK8TTKCDK4 | |
| SCHEMBL16823256 | 0.89 | JUN (0.51) | MAPK10JUNMAPK8TTKCDK4 | |
| SCHEMBL29847787 | 0.89 | JUN (0.51) | MAPK10JUNMAPK8TTKCDK4 | |
| SCHEMBL16823087 | 0.89 | JUN (0.48) | MAPK10JUNMAPK8TTKCDK4 | |
| SCHEMBL29847920 | 0.89 | JUN (0.48) | MAPK10JUNMAPK8TTKCDK4 | |
| SCHEMBL16513949 | 0.88 | ERBB3 (0.42) | CDK4CCND1CDK1CCNB1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105682661-B | Certain chemical entities, compositions, and methods | 润新生物公司 | 2020-03-27 | — | — | CN | claimed |
| US-9849139-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2017-12-26 | — | — | US | claimed |
| US-20170196881-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA, INC. | 2017-07-13 | — | — | US | claimed |
| US-9550770-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2017-01-24 | — | — | US | claimed |
| US-20150175601-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2015-06-25 | — | — | US | claimed |
| US-20260102406-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12403145-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC (US) | 2025-09-02 | — | — | US | disclosed |
| US-20240197752-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA INC | 2024-06-20 | — | — | US | disclosed |
| US-11865120-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| US-20220354864-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA, INC. | 2022-11-10 | — | — | US | disclosed |
| CN-109851617-B | Chemical entities, compositions, and methods | 润新生物公司 | 2022-08-16 | — | — | CN | disclosed |
| US-11304957-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2022-04-19 | — | — | US | disclosed |
| EP-3035936-B1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA INC (US) | 2019-03-13 | — | — | EP | disclosed |
| US-10172868-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180125855-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA, INC. | 2018-05-10 | — | — | US | disclosed |
| US-9849139-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170196881-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA, INC. | 2017-07-13 | — | — | US | disclosed |
| US-20170050936-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2017-02-23 | — | — | US | disclosed |
| US-9550770-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20150175601-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2015-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10172868-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | MAPK10 347/4885JUN 1830/4885MAPK8 212/4885 |
| US-20170196881-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | DCK, ABL1, MAP4K2 | MAPK10 347/4885JUN 1830/4885MAPK8 212/4885 |
| US-20240197752-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | DCK, ABL1, MAP4K2 | MAPK10 347/4885JUN 1830/4885MAPK8 212/4885 |
| US-11865120-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | MAPK10 347/4885JUN 1830/4885MAPK8 212/4885 |
| US-20150175601-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, PIK3CA, PLK1 | MAPK10 395/4885JUN 3073/4885MAPK8 246/4885 |
| US-12403145-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | MAPK10 347/4885JUN 1830/4885MAPK8 212/4885 |
| US-20180125855-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | DCK, ABL1, MAP4K2 | MAPK10 347/4885JUN 1830/4885MAPK8 212/4885 |
| US-11304957-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | MAPK10 347/4885JUN 1830/4885MAPK8 212/4885 |
| US-20220354864-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | DCK, ABL1, MAP4K2 | MAPK10 347/4885JUN 1830/4885MAPK8 212/4885 |
| US-20170050936-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CDK2, MAP3K6, MAP3K2 | MAPK10 314/4885JUN 604/4885MAPK8 156/4885 |
| US-20260102406-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | BRAF, TTK, MAP4K2 | MAPK10 220/4885JUN 1577/4885MAPK8 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.